Med Sci Monit:ATN-161作为整合素α5β1拮抗剂通过促进新生血管内皮细胞凋亡抑制眼部新生血管形成

2018-08-28 MedSci MedSci原创

上海交通大学医学院瑞金医院眼科的Sui A和Zhong Y等近日在Med Sci Monit发表了一篇重要的研究文章。他们在小鼠模型中调查了ATN-161调节眼部血管生成中的作用,并探索了潜在的信号传导途径。

上海交通大学医学院瑞金医院眼科的Sui A和Zhong Y等近日在Med Sci Monit发表了一篇重要的研究文章。他们在小鼠模型中调查了ATN-161调节眼部血管生成中的作用,并探索了潜在的信号传导途径。

ATN-161(Ac-PHSCN-NH2)是整联蛋白α5β1的拮抗剂,已有研究指出,在抑制肿瘤血管生成和转移中具有重要作用。然而,ATN-161的作用机制及其是否能抑制眼部新生血管(NV)尚不清楚。

采用氧诱导视网膜病变(OIR)小鼠模型和激光诱导脉络膜新生血管(CNV)小鼠模型,通过免疫荧光染色、Western blot分析,检测整合素a5b1的表达及ATN-161对眼NV的影响。免疫荧光染色、Western blot、real-time RT-PCR和末端脱氧核苷酸转移酶检测核因子-κB(NF-κB)、基质金属蛋白酶-2 / 9(MMP-2/9)的活化及细胞凋亡。通过BrdU标记检测细胞增殖。

与年龄匹配的对照组相比,结果在OIR和CNV小鼠中,整合素α5β1的蛋白表达水平显着增加。进行ATN-161处理的小鼠视网膜新血管形成(RNV)和CNV显着减少。ATN-161可以阻断整合素a5b1,强烈抑制核因子-κB(NF-κB)活化和基质金属蛋白酶-2 / 9(MMP-2/9)的表达,促进细胞凋亡,但ATN-161对CNV小鼠模型中的血管增殖的影响是间接的,需要抑制新血管形成。吡咯烷二硫代氨基甲酸铵(PDTC)抑制NF-κB活化,可降低RNV,促进眼内NV细胞的凋亡。

因此,他们认为,ATN-161阻断整合素α5β1,通过抑制MMP-2 / MMP-9表达,促进眼内细胞凋亡来降低眼内新生血管。

原文出处:

Sui, A., et al., ATN-161 as an Integrin alpha5beta1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis. Med Sci Monit, 2018. 24: p. 5860-5873.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2019-02-26 huiwelcome
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1703974, encodeId=c7db1e039742f, content=<a href='/topic/show?id=64e05854824' target=_blank style='color:#2F92EE;'>#新生血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58548, encryptionId=64e05854824, topicName=新生血管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68830606495, createdName=chenzhuanggui, createdTime=Tue Jun 11 21:51:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936603, encodeId=ae8e193660323, content=<a href='/topic/show?id=47be895549f' target=_blank style='color:#2F92EE;'>#血管内皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89554, encryptionId=47be895549f, topicName=血管内皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Tue Aug 06 15:51:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053512, encodeId=d3fb205351259, content=<a href='/topic/show?id=2ee15e815ce' target=_blank style='color:#2F92EE;'>#整合素α5β1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57815, encryptionId=2ee15e815ce, topicName=整合素α5β1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Thu Aug 30 08:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776073, encodeId=8acc1e760734c, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Tue Feb 26 02:51:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340281, encodeId=5e63134028134, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459461, encodeId=2d9d14594614c, content=<a href='/topic/show?id=210e5e814f2' target=_blank style='color:#2F92EE;'>#整合素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57814, encryptionId=210e5e814f2, topicName=整合素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511712, encodeId=55221511e12fb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609083, encodeId=919e160908326, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Aug 30 02:51:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341464, encodeId=c831341464c5, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 28 13:43:50 CST 2018, time=2018-08-28, status=1, ipAttribution=)]
    2018-08-28 liumin1987

    谢谢分享,学习了。

    0